drugset / Trial / NCT03059485
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Phase 2
Active not recruiting
82 enrolled
Beth Israel Deaconess Medical Center
Celgene Corporation · collabDana-Farber Cancer Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying a cancer vaccine called Dendritic Cell/AML Fusion vaccine (DC/AML vaccine) as a possible treatment for Acute Myelogenous Leukemia (AML). The interventions involved in this study are: -Dendritic Cell/AML Fusion vaccine (DC/AML vaccine)
Timeline
- Start
- 2017-06-01
- Primary completion
- 2026-09-04
- Completion
- 2026-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC/AML Fusion Vaccine | Vaccine | — | — |